Attached files
| file | filename |
|---|---|
| EX-99.1 - RESPONSE GENETICS INC | v210248_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 4,
2011
RESPONSE
GENETICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
(State
or other
jurisdiction
of
incorporation)
|
000-1124608
(Commission File
Number)
|
11-3525548
(IRS Employer
Identification
No.)
|
1640
Marengo St., 6th Floor
Los
Angeles, California 90033
(323)
224-3900
(Address,
including zip code, and telephone number, including area code, of registrant’s
principal executive offices)
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
5.02. Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers; Compensatory Arrangements of
Certain Officers.
On
February 7, 2011, Response Genetics, Inc. (the “Company”) announced the
appointment of Christine Meda as the Company’s President, effective February 4,
2011. Kathleen Danenberg, who previously held the position of
President of the Company, will continue to act as Chief Executive Officer of the
Company. In her role, Ms. Meda will be responsible for helping in the
execution of the Company’s strategy and operations on a day-to-day basis and,
with her unique expertise in cancer diagnostics, leading the Company in new
areas of the market, such as the development of companion
diagnostics.
Most
recently, Ms. Meda, age 62, was President and Chief Executive Officer of Arcxis
Biotechnologies, an early-stage molecular diagnostics company, where she had
worked since December 2007. Ms. Meda founded and is also President of
RxDxLink, a consulting service company to early stage and small biotechnology
companies. Ms. Meda served as President and Chief Operating Officer
for Diamics, Inc., an early-stage diagnostics company, from January 2007 to July
2007. From January 2003 through 2006, Ms. Meda held various
positions, including Vice President Business Development and Vice President of
Women’s Health Development, at Roche Molecular Diagnostics, where she was
responsible for research medical device business strategy. Ms. Meda
received a B.S. from the State University of New York, Potsdam
Campus.
The
Company will compensate Ms. Meda with a base salary of approximately $300,000
per year, along with a potential bonus of 35% of her base salary, based on
particular goals to be determined for a position of this level. Ms.
Meda will also receive an option grant in connection with her appointment of at
least 100,000 stock options. The Company intends to enter into a
formal employment agreement with Ms. Meda within the first half of the Company’s
2011 fiscal year.
Item
9.01. Financial Statements and Exhibits
(d) The
following exhibits are being filed with this report
Exhibit
Number Document
Description
99.1
Press Release dated February 7, 2011
- 2
-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
RESPONSE GENETICS,
INC.
|
|||
|
Dated:
February 7, 2011
|
By: /s/ Kathleen Danenberg | ||
| Name: Kathleen Danenberg | |||
|
Title:
Chief Executive Officer
|
|||
- 3
-